MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Drug-induced lupus erythematosus
Drug-induced lupus erythematosus
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Drug-induced lupus erythematosus
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Drug-induced lupus erythematosus
Drug-induced lupus erythematosus

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Drug-induced lupus erythematosus
Drug-induced lupus erythematosus
Journal Article

Drug-induced lupus erythematosus

2009
Request Book From Autostore and Choose the Collection Method
Overview
Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation of the offending drug. There are currently no standard diagnostic criteria for DILE and the pathomechanisms are still unclear. Similarly to idiopathic lupus, DILE can be diveded into systemic (SLE), subacute cutaneous (SCLE) and chronic cutaneous lupus (CCLE). Systemic DILE is characterized by typical lupus-like symptoms including skin signs, usually mild systemic involvement and a typical laboratory profile with positive antinuclear and anti-histone antibodies, while anti-double strand (ds) DNA and anti-extractable nuclear antigens antibodies are rare. High risk drugs include hydralazine, procainamide and isoniazid. Drug-induced SCLE is very similar to idiopathic SCLE in terms of clinical and serologic characteristic, and it is more common than the systemic form of DILE. Drugs associated with SCLE include calcium channel blockers, angiotensin-converting enzyme inhibitors, interferons, thiazide diuretics and terbinafine. Drug-induced CCLE is very rarely reported in the literature and usually refers to fluorouracile agents or non steroidal anti-inflammatory drugs. Recently, cases of DILE have been reported with anti-TNFα agents. These cases present with disparate clinical features including arthritis/arthralgia, skin rash, serositis, cytopenia and variable laboratory abnormalities. DILE to anti-TNFα agents differs in several ways to classic DILE. The incidence of rashes is higher compared to classical systemic DILE. In most cases of classic DILE visceral involvement is rare, whereas several cases of anti-TNFα DILE with evidence of renal disease have been reported. Low serum complement levels as well as anti-extractable nuclear antigen antibodies and anti-dsDNA antibodies are rarely present in classic DILE, whereas they are reported in half the cases of anti-TNFα DILE; in contrast, anti-histone antibodies are described in classic DILE more often than in anti-TNFα DILE. Recognition of DILE in patients receiving anti-TNFα therapy can be difficult due to the symptoms of their underlying disease. A temporal association (months to years) of the offending drug with characteristic or suggestive symptoms, and resolution of symptoms on drug withdrawal is the best evidence for this diagnosis of DILE.
Publisher
Berlin/Heidelberg : Springer-Verlag,Springer-Verlag,Springer,Springer Nature B.V
Subject

Angiotensin-Converting Enzyme Inhibitors - administration & dosage

/ Angiotensin-Converting Enzyme Inhibitors - adverse effects

/ Animals

/ Anti-Arrhythmia Agents - administration & dosage

/ Anti-Arrhythmia Agents - adverse effects

/ Antibodies - immunology

/ Antibodies - metabolism

/ Antifungal Agents - administration & dosage

/ Antifungal Agents - adverse effects

/ Antihypertensive Agents - administration & dosage

/ Antihypertensive Agents - adverse effects

/ Antitubercular Agents - administration & dosage

/ Antitubercular Agents - adverse effects

/ Arthritis

/ Biological and medical sciences

/ Calcium Channel Blockers - administration & dosage

/ Calcium Channel Blockers - adverse effects

/ Dermatology

/ Exanthema

/ Humans

/ Hydralazine - administration & dosage

/ Hydralazine - adverse effects

/ Interferons - administration & dosage

/ Interferons - adverse effects

/ Isoniazid - administration & dosage

/ Isoniazid - adverse effects

/ Lupus Erythematosus, Cutaneous - chemically induced

/ Lupus Erythematosus, Cutaneous - diagnosis

/ Lupus Erythematosus, Cutaneous - immunology

/ Lupus Erythematosus, Systemic - chemically induced

/ Lupus Erythematosus, Systemic - diagnosis

/ Lupus Erythematosus, Systemic - immunology

/ Medical sciences

/ Medicine

/ Medicine & Public Health

/ Naphthalenes - administration & dosage

/ Naphthalenes - adverse effects

/ Procainamide - administration & dosage

/ Procainamide - adverse effects

/ Review

/ Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis

/ Serositis

/ Sodium Chloride Symporter Inhibitors - administration & dosage

/ Sodium Chloride Symporter Inhibitors - adverse effects

/ Tumor Necrosis Factor-alpha - immunology